To include your compound in the COVID-19 Resource Center, submit it here.

Amgen, UCB report CV safety signal in Phase III of osteoporosis candidate Evenity

By Mary Romeo | May 26, 2017 | 5:17 PM GMT

Amgen Inc. (NASDAQ:AMGN) and UCB S.A. (Euronext:UCB) no longer expect FDA to approve Evenity romosozumab (AMG 785, CDP7851) this year after data from the Phase III ARCH trial in 4,093 postmenopausal women with osteoporosis at high risk for fracture revealed a previously unseen cardiovascular

Read the full 443 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE